Phospho-IRF3 (Ser386) Antibody

What is the functional significance of IRF3 Ser386 phosphorylation in innate immunity?

Phosphorylation at Ser386 represents a critical regulatory event in IRF3 activation. Upon viral infection, IRF3 undergoes phosphorylation at this residue, which serves as an essential trigger for its dimerization and subsequent association with the CREB-binding protein (CBP/p300) coactivator complex . This phosphorylation event enables IRF3 to translocate to the nucleus where it activates promoters containing IRF3-binding sites, leading to the transcription of type I interferon genes and interferon-stimulated genes . This cascade forms the cornerstone of the innate immune response against DNA and RNA viruses. Experimentally, mutation studies have conclusively demonstrated that alterations at Ser386 abolish the dimerization potential of IRF3, thereby preventing downstream signaling events .

How does Ser386 phosphorylation differ mechanistically from other phosphorylation sites on IRF3?

The IRF3 C-terminal regulatory domain contains multiple phosphoacceptor sites organized in three clusters:

• Cluster I: Ser385/Ser386

• Cluster II: Ser396/Ser398

• Cluster III: Ser402/Thr404/Ser405

Crystallographic studies have revealed that Ser386 is positioned in a highly accessible region, making it the likely initial target for TBK1/IKKi kinases . In contrast to Ser396 phosphorylation, which plays a moderate role in IRF3 activation, Ser386 phosphorylation is absolutely essential, as demonstrated by the complete loss of function in S386A mutants . Interestingly, structure-function studies have shown that phosphomimetic substitutions (S386D) also abrogate IRF3 activation, suggesting that the precise chemical nature of the phosphorylation is critical for proper function .

What are the relative advantages of using monoclonal versus polyclonal Phospho-IRF3 (Ser386) antibodies in research applications?

Selection between monoclonal and polyclonal antibodies depends on specific research requirements:

For longitudinal studies requiring consistent detection over extended periods, monoclonal antibodies offer superior reproducibility . Conversely, when working with challenging samples or when signal amplification is needed, polyclonal antibodies may provide greater sensitivity . In validation studies, researchers typically confirm findings using both antibody types to ensure robustness of results and rule out potential artifacts from antibody-specific binding characteristics .

How can researchers quantitatively measure IRF3 Ser386 phosphorylation in different experimental systems?

Multiple quantitative approaches exist for measuring IRF3 Ser386 phosphorylation, each with distinct advantages:

• Cell-Based ELISA Methods:

  • Indirect ELISA format uses anti-phospho-IRF3 (Ser386) antibodies for capture, with dye-conjugated secondary antibodies enabling fluorometric detection

  • Requires normalization using anti-IRF3 antibodies to account for total protein levels

  • Allows for high-throughput screening of stimulation conditions across different cell lines

• HTRF (Homogeneous Time-Resolved Fluorescence):

  • Employs a no-wash assay format using two labeled antibodies: one specific to the phosphorylated motif, another recognizing total protein

  • Creates a FRET signal proportional to phosphorylated protein concentration

  • Offers increased throughput compared to traditional Western blot methods

  • Sample protocol follows a two-plate approach: culture cells in 96-well plates, then transfer lysates to 384-well detection plates

• Western Blot Quantification:

  • Provides information on protein size and antibody specificity

  • Recommended dilution for phospho-IRF3 (Ser386) antibodies: 1:1000

  • Requires careful validation with appropriate controls including phosphatase-treated samples

• Flow Cytometry:

  • Enables single-cell analysis of phospho-IRF3 status

  • Requires cell fixation/permeabilization protocols (recommended dilution: 1:400-1:1600)

  • Allows correlation with other cellular parameters

The selection of method should be tailored to experimental objectives, with ELISA and HTRF being preferable for high-throughput screening, while Western blotting provides greater specificity for mechanistic studies .

How does the mechanism of IRF3 Ser386 phosphorylation differ between viral families, and what experimental designs can distinguish these pathways?

The mechanism of IRF3 Ser386 phosphorylation exhibits differential characteristics depending on the viral family involved:

For rigorous experimental distinction between these pathways, researchers should:

• Employ pathway-specific inhibitors (e.g., STING inhibitors, TBK1/IKKε inhibitors)

• Use cells with CRISPR/Cas9-mediated deletion of pathway components

• Analyze phosphorylation kinetics with high temporal resolution (15min, 30min, 1h, 2h, 4h, 8h post-infection)

• Employ phospho-specific antibodies against multiple IRF3 sites simultaneously (Ser386, Ser396, Thr390)

• Utilize mass spectrometry to identify the complete phosphorylation pattern induced by different viral families

This comprehensive approach enables researchers to delineate the virus-specific signatures of IRF3 activation and identify potential targets for immunomodulation .

What is the current understanding of sequential phosphorylation models for IRF3 activation, and how does Ser386 phosphorylation fit within these models?

Multiple models have been proposed to explain the sequential phosphorylation events leading to IRF3 activation:

• Ser386-Initiated Model:

  • Phosphorylation at Ser386 serves as the initial critical event

  • Induces conformational changes enabling subsequent phosphorylation at other sites

  • Supported by findings that S386A mutations completely abolish activation

• Two-Step Model:

  • Initial phosphorylation at cluster II (Ser396 region) alleviates auto-inhibition

  • This facilitates subsequent phosphorylation at Ser386, leading to full activation

  • Supported by studies showing that S396D mutations can induce partial activation

• Multi-Site Feedback Model:

  • Proposes sequential phosphorylation: Ser385/386 → Ser396 → Thr390 → Ser396 (in a feedback mechanism)

  • Indicates cooperativity between multiple phosphorylation events

  • Based on mass spectrometry identification of in vivo phosphorylation patterns

Recent structural and functional studies provide stronger support for the Ser386-Initiated Model, as crystallographic data reveals that:

• Ser386 phosphorylation creates a specific binding pocket for dimerization

• This dimerization is essential for interaction with CBP/p300

• Mutations at Ser386 prevent all downstream activation events

To experimentally distinguish between these models, researchers can employ:

• Phospho-mimetic mutations in different combinations

• Time-course analyses with phospho-specific antibodies

• Mass spectrometry to track phosphorylation sequence

• Structural studies of IRF3 in different phosphorylation states

What are the common sources of false positives/negatives when using Phospho-IRF3 (Ser386) antibodies, and how can researchers validate antibody specificity?

Several factors can contribute to erroneous results when using phospho-specific antibodies:

A rigorous validation protocol should include:

• Control samples:

  • Unstimulated cells (negative control)

  • Cells treated with known IRF3 activators (positive control)

  • Phosphatase-treated lysates (specificity control)

• Genetic controls:

  • IRF3 knockout cell lines

  • IRF3 S386A mutant-expressing cells

• Antibody specificity tests:

  • Peptide competition assays using phospho- and non-phospho-peptides

  • Detection using alternative antibody clones

• Complementary techniques:

  • Confirmation with mass spectrometry

  • Correlation with functional readouts (e.g., IFN-β reporter assays)

How can researchers optimize detection conditions for low abundance Phospho-IRF3 (Ser386) in primary cells and tissue samples?

Primary cells and tissues present unique challenges for phospho-IRF3 detection due to lower abundance and increased background. Optimized protocols include:

• Improved Extraction Methods:

  • Use specialized lysis buffers containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate)

  • Add protease inhibitors to prevent degradation

  • Perform rapid extraction at 4°C to preserve phosphorylation status

• Signal Amplification Strategies:

  • Employ tyramide signal amplification for immunohistochemistry/immunofluorescence

  • Use biotin-streptavidin amplification systems

  • Consider proximity ligation assays to detect phospho-IRF3 interactions with binding partners

• Enrichment Techniques:

  • Immunoprecipitate IRF3 before phospho-detection

  • Use phospho-protein enrichment columns

  • Perform subcellular fractionation to concentrate nuclear phospho-IRF3

• Optimized Detection Parameters:

  • For Western blotting: Increase protein loading (50-100 μg); Use high-sensitivity ECL substrates

  • For immunofluorescence: Extend primary antibody incubation (overnight at 4°C); Use higher antibody concentration (1:200-1:400)

  • For flow cytometry: Optimize permeabilization conditions; Extend antibody incubation times

• Validation Controls:

  • Include phosphatase-treated negative controls

  • Use appropriate positive controls (virus-infected samples)

  • Compare results with orthogonal detection methods

These approaches significantly enhance detection sensitivity while maintaining specificity in challenging primary samples .

How does IRF3 Ser386 phosphorylation influence interactions with other signaling pathways beyond type I interferon responses?

IRF3 Ser386 phosphorylation serves as a central node connecting multiple signaling networks:

• Apoptosis Regulation:

  • Phosphorylated IRF3 interacts with the TOMM70:HSP90AA1:BAX complex at mitochondria following Sendai virus infection

  • This interaction forms an apoptosis-inducing complex independent of its transcriptional activity

  • IRF3 can induce significant apoptosis in primary macrophages through this mechanism

• Cross-regulation with NF-κB Signaling:

  • Phospho-IRF3 (Ser386) can modulate NF-κB-dependent inflammatory responses

  • The interplay affects the balance between antiviral and inflammatory cytokine production

  • Experimental evidence indicates shared and distinct gene expression programs regulated by these pathways

• Metabolic Reprogramming:

  • Growing evidence suggests phospho-IRF3 influences cellular metabolic states during infection

  • This includes alterations in mitochondrial function and oxidative phosphorylation

  • Experimental approaches using metabolic inhibitors reveal IRF3-dependent metabolic shifts

• Autophagy Modulation:

  • Phospho-IRF3 can influence autophagy induction following viral infection

  • This represents a complementary antiviral mechanism distinct from interferon production

To experimentally investigate these interconnections, researchers can:

• Perform co-immunoprecipitation studies using phospho-specific antibodies

• Conduct ChIP-seq analysis to identify genome-wide binding sites

• Employ proximity labeling techniques (BioID, APEX) to identify novel interaction partners

• Utilize phospho-IRF3 (S386A) mutants to distinguish phosphorylation-dependent processes

What are the emerging technologies for studying the spatiotemporal dynamics of IRF3 Ser386 phosphorylation in living cells?

Cutting-edge approaches for monitoring IRF3 phosphorylation dynamics include:

• Phospho-specific Biosensors:

  • FRET-based sensors incorporating IRF3 phospho-binding domains

  • Enables real-time visualization of phosphorylation events

  • Can reveal subcellular localization patterns of phospho-IRF3

  • Experimental design: Construct sensors using the IRF3 phospho-binding domain from CBP/p300 paired with appropriate fluorophores

• Live-Cell Single-Molecule Imaging:

  • Tracks individual IRF3 molecules following stimulation

  • Reveals heterogeneity in phosphorylation kinetics at single-cell level

  • Implementation requires fluorescently tagged IRF3 and advanced microscopy platforms

• Phospho-proteomic Mass Spectrometry with SILAC or TMT Labeling:

  • Provides quantitative temporal profiles of multiple phosphorylation sites

  • Reveals sequential phosphorylation patterns following stimulation

  • Enables discovery of previously uncharacterized phosphorylation sites

• Light-regulated IRF3 Variants:

  • Optogenetic tools to control IRF3 dimerization or kinase activity

  • Enables precise temporal control of pathway activation

  • Allows dissection of phosphorylation sequence and downstream effects

• Single-cell Phospho-Flow Cytometry:

  • Measures phospho-IRF3 levels across heterogeneous cell populations

  • Enables correlation with other signaling events in individual cells

  • Particularly valuable for studying primary clinical samples

These approaches have revealed that IRF3 phosphorylation occurs with distinct kinetics in different subcellular compartments, challenging previous models of sequential cytoplasmic-to-nuclear translocation .